Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Leblanc

Showing results (51-60 of 120) with videos related to

Pageof 12
Sort By:
Cytometry. Part B, Clinical Cytometry|November 14, 2024
Improved identification of clinically relevant Acute Leukemia subtypes using standardized EuroFlow panels versus non-standardized approachRafik Terra, Vincent Éthier, Lambert Busque, et al.
Journal of the American Society of Nephrology : JASN|September 7, 2014
IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometryVirginie Royal, Patrick Quint, Martine Leblanc, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 5, 2006
Asynchronous differentiation of CD8 T cells that recognize dominant and cryptic antigensChantal Baron, Marie-Christine Meunier, Etienne Caron, et al.
Cancer Medicine|September 3, 2024
Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemiaCamille Tessier, Richard LeBlanc, Jean Roy, et al.
Cancer Research|April 17, 2002
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in miceSuzanne Lentzsch, Michael S Rogers, Richard LeBlanc, et al.
Journal of Neurosurgery|March 17, 2009
Low-grade oligodendroglioma: an indolent but incurable disease? Clinical articleHamdy El-Hateer, Luis Souhami, David Roberge, et al.
Leukemia & Lymphoma|July 9, 2008
Treatment of relapsed and refractory myelomaDonna E Reece, Heather A Leitch, Harold Atkins, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2023
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple MyelomaJulie Stakiw, Shruthi Kodad, Richard LeBlanc, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 20, 2024
First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline ConsortiumSahar Khan, Debra J Bergstrom, Julie Côté, et al.
Plos One|February 27, 2026
Using virtual reality hypnosis during stem cell transplant for patients in hematology: A protocol for a feasibility randomized studyAudrey Laurin, Floriane Rousseaux, Valentyn Fournier, et al.
Pageof 12

Showing results (51-60 of 120) with videos related to

Sort By:
Pageof 12
Cytometry. Part B, Clinical Cytometry|November 14, 2024
Improved identification of clinically relevant Acute Leukemia subtypes using standardized EuroFlow panels versus non-standardized approachRafik Terra, Vincent Éthier, Lambert Busque, et al.
Journal of the American Society of Nephrology : JASN|September 7, 2014
IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometryVirginie Royal, Patrick Quint, Martine Leblanc, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 5, 2006
Asynchronous differentiation of CD8 T cells that recognize dominant and cryptic antigensChantal Baron, Marie-Christine Meunier, Etienne Caron, et al.
Cancer Medicine|September 3, 2024
Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemiaCamille Tessier, Richard LeBlanc, Jean Roy, et al.
Cancer Research|April 17, 2002
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in miceSuzanne Lentzsch, Michael S Rogers, Richard LeBlanc, et al.
Journal of Neurosurgery|March 17, 2009
Low-grade oligodendroglioma: an indolent but incurable disease? Clinical articleHamdy El-Hateer, Luis Souhami, David Roberge, et al.
Leukemia & Lymphoma|July 9, 2008
Treatment of relapsed and refractory myelomaDonna E Reece, Heather A Leitch, Harold Atkins, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2023
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple MyelomaJulie Stakiw, Shruthi Kodad, Richard LeBlanc, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 20, 2024
First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline ConsortiumSahar Khan, Debra J Bergstrom, Julie Côté, et al.
Plos One|February 27, 2026
Using virtual reality hypnosis during stem cell transplant for patients in hematology: A protocol for a feasibility randomized studyAudrey Laurin, Floriane Rousseaux, Valentyn Fournier, et al.
Pageof 12